Advanced visualization and image analytics software developer Qmenta has won a contract to provide imaging data management, analysis, and visualization services for an upcoming Alzheimer's clinical trial of the AMX0035 drug candidate from Amylyx Pharmaceuticals.
The Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease is known as PEGASUS. With its cloud-based neuroimaging platform, Qmenta will help Amylyx analyze MRI data collected as part of the trial, it said.
The trial is funded by the Alzheimer's Combination Therapeutics Opportunity initiative, which is a collaboration between the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation.
